---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-043424"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-04-07T23:59:59+00:00"
generated_at: "2026-06-26T08:51:54.999598+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics appoints Wendy L. Dixon to board; Brad Bolzon resigns

## Summary
- Brad Bolzon resigned from the Board effective April 5, 2022; not due to any disagreement with the company.
- Wendy L. Dixon, Ph.D., appointed as Class III director effective April 6, 2022; deemed independent under Nasdaq rules.
- Dr. Dixon brings over 40 years biopharma experience, including former CMO of Bristol Myers Squibb and board seats at Alkermes, Incyte, Arvinas.
- She will receive standard non-employee director compensation and enter into an indemnification agreement.

## SEC filing metadata
- accession: 0001104659-22-043424
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/tm2211759d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-043424
- JSON: https://secwatch.observer/filing/0001104659-22-043424.json
- Plain text: https://secwatch.observer/filing/0001104659-22-043424.txt

## Key facts
- Executive change
  Brad Bolzon resigned as Director at Black Diamond Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm
- Executive change
  Wendy L. Dixon was appointed as Class III Director at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On April 6, 2022 (the “Effective Date”), upon the recommendation of its Compensation, Nomination and Corporate Governance Committee, the Board appointed Wendy L. Dixon, Ph.D. to serve on the Board as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.